Ceballos-López AA

Idioma: Español
Referencias bibliográficas: 36
Paginas: 17-23
Archivo PDF: 269.14 Kb.

RESUMEN

Aunque la incidencia y prevalencia exacta de la leucemia linfocítica crónica en México se desconocen, de acuerdo con datos epidemiológicos publicados se considera la leucemia menos frecuente tomando en cuenta las leucemias agudas y crónicas. En contraste, en Europa y Estados Unidos la leucemia linfocítica crónica es la leucemia más frecuente. Se han descrito factores de pronóstico y predictivos de la enfermedad, pero en los últimos años existe evidencia que demuestra que lograr una enfermedad mínima residual negativa, sin importar los factores de pronóstico de base o el tratamiento prescrito, es el factor predictivo más importante que repercute en el tiempo libre de progresión y en la supervivencia global. En este artículo se analizan los métodos para evaluar la enfermedad mínima residual, de dónde obtener la muestra para al análisis de la misma y las tasas de enfermedad mínima residual negativas que se obtienen con diferentes esquemas terapéuticos tratando de validarlos en la realidad mexicana.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Houlston RS, Catovsky D, Yuille MR. Genetic susceptibility to chronic lymphocytic leukemia. Leukemia 2002;16(6):1008-14.

2. Aleman-Hoey DD, Ruiz-Arguelles GJ, Verduzco-Rodriguez L, Lopez-Ariza B, Labardini JR. Chronic lymphocytic leukemia 1. Thirty five years experience at the Instituto Nacional de la Nutricion Salvador Zubiran. Rev Invest Clin 1982;34(2):151-6.

3. Ruiz-Argüelles GJ. Advances in the diagnosis and treatment of acute and chronic leukemia in Mexico. Salud Pública Méx 2016;58(2):291-5.

4. Ruiz-Argüelles G, Velázquez B, Apreza-Molina M, Pérez- Romano B, Ruiz-Reyes G, Ruiz-Argüelles A. Chronic lymphocytic leukemia is infrequent in Mexican mestizos. Int J Hematol 1999;69(4):253-5.

5. Santoyo-Sánchez A, Ramos-Peñafiel CO, Saavedra-González A, et al. Frecuencias de edad y género de pacientes con leucemia en dos centros de referencia del Valle de México. Gac Méd Méx 2017;153(1):44-8.

6. Gómez-Almaguer D. Leucemia linfocítica crónica en México. Rev Hematol Mex 2017;Supl 1(18):51-52.

7. Kwok M, Rawstron AC, Varghese A, et al. Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood 2016;128(24):2770-3.

8. Davis RS, Fletcher CD, Hill B, et al. NCCN Guidelines Index Table of Contents Discussion Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma. 2018.

9. Thompson PA, Tam CS, O’Brien SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-Term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 2016;127(3):303-9.

10. Edelmann J, Tausch E, Landau DA, et al. Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: Results from the CLL8 trial. Leukemia 2017;31(3):734-8.

11. Castellanos RC, Ibarra MA, Pantoja EÁ, et al. Primer consenso en leucemia linfocítica crónica de la Agrupación Mexicana para el Estudio de la Hematología: epidemiología, diagnóstico y tratamiento. Med Univ 2008;10(40):159-67.

12. Thompson M, Brander D, Nabhan C, Mato A. Minimal residual disease in chronic lymphocytic leukemia in the era of novel agents. JAMA Oncol 2017.

13. Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007;21(5):956-64.

14. Rawstron A, Fazi C, Agathangelidis A, et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia 2016;30:929-36.

15. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111(12):5446-56.

16. Rodrigues CA, Gonçalves MV, Ikoma MRV, et al. Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia. Rev Bras Hematol e Hemoter 2016;38:346-57.

17. García Vela JA, García Marco JA. Enfermedad mínima residual en la leucemia linfocítica crónica. Med Clin (Barc) 2017.

18. Thompson PA, Wierda WG. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood 2016;127(3):279-86.

19. Rawstron AC, Howard D, McParland L, et al. Compartment effect on the prognostic significance of MRD detection in CLL: Impact of treatment type and duration of follow-up. Blood 2016;128(22):3226.

20. Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012;30(26):3209-16.

21. Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 2014;123(12):1810-17.

22. O’Brien SM, Furman RR, Coutre SE, et al. Five-Year experience with single-agent ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. Blood 2016;128(22):233.

23. Kovacs G, Robrecht S, Fink AM, et al. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: Comprehensive analysis of two phase III Studies of the German CLL Study Group. J Clin Oncol 2016;34(31):3758-65.

24. Strati P, Keating MJ, O’Brien SM, et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood 2014;123(24):3727- 32.

25. Seymour JF, Ma S, Brander DM, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol 2017;18(2):230-40.

26. Roberts AW, Seymour JF, Eichhorst B, et al. Pooled multitrial analysis of venetoclax efficacy in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2016;128(22):3230.

27. Jones J, Choi MY, Mato AR, et al. Venetoclax (VEN) Monotherapy for patients with chronic lymphocytic leukemia (CLL) Who relapsed after or were refractory to ibrutinib or idelalisib. Blood 2016;128(22):637.

28. Weiss MA, Glenn M, Maslak P, et al. Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy. Leukemia 2000;14(9):1577-82.

29. Schweighofer CD, Ritgen M, Eichhorst BF, et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission - Long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol 2009;144(1):95-8.

30. Fink AM, Bahlo J, Sandra R, et al. Lenalidomide maintenance after front line therapy substantially prolongs progression free survival in high risk CLL: Interim results of a phase 3 study (CLL M1 study of the German CLL Study Group). Blood 2016;128(22):229.

31. Böttcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: A multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012;30(9):980-8.

32. Eichhorst B, Fink AM, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, noninferiority trial. Lancet Oncol 2016;17(7):928-42.

33. Sharman JP, Yimer HA, Boxer M, et al. Results of a phase II multicenter study of obinutuzumab plus bendamustine in pts with previously untreated chronic lymphocytic leukemia (CLL). J Clin Oncol 2017;35(Suppl 15):7523.

34. Goede V, Fischer K, Bosch F, et al. Updated survival analysis from the CLL11 study: Obinutuzumab versus rituximab in chemoimmunotherapy-treated patients with chronic lymphocytic leukemia. ASH 2015;126:1733.

35. Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol 2017;17(2):200-11.

36. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 2016;17(6):768-78.